Vertex Pharmaceuticals Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRTX research report →
Range $350 – $665
Price Chart
About the company
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.
- CEO
- Reshma Kewalramani
- IPO
- 1991
- Employees
- 6,400
- HQ
- Boston, MA, US
AI snapshot
Six angles, distilled from the data.
VRTX remains in a strong multi-month uptrend, trading above both the 50-day and 200-day moving averages. The stock sits near the upper end of its 52-week range, which keeps the secular setup constructive even after recent consolidation from the highs.
Street sentiment stays firmly constructive, with a Buy consensus and a $579.29 average target versus a $531.32 share price. Recent target revisions have skewed higher, including moves to $619, $650, $575, and $570, even as a few firms kept existing positive ratings unchanged.
Earnings have been mixed, with 4 beats in the last 8 quarters and a recent miss of 3.4% versus estimates. The next-year EPS view points to $19.92 from $15.54 TTM, so shareholders should watch whether margin discipline and product momentum keep that path intact.
Recent insider activity leans to net selling, led by two large discretionary sales from the CEO and an EVP/CFO. The rest of the activity is mostly awards, gifts, and other non-market transactions, which carry less signal than the open-market sales.
VRTX combines strong profitability with solid growth: gross margin is 54.8%, operating margin 37.79%, and net margin 30.7%. Revenue grew 11.8% year over year, while free cash flow reached $4.069 billion and the balance sheet held $4.578 billion in net cash.
VRTX still screens as a premium biotech franchise, supported by high margins, net cash, and a 0.28 beta that reflects lower market sensitivity. The valuation remains rich versus the sector, with a 28.07 P/E and a market cap above $135 billion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $130.58B
- P/E
- 34.26
- Fwd P/E
- 28.37
- PEG
- 3.69
- P/S
- 10.50
- P/B
- 6.50
- EV/EBITDA
- 28.38
- Div Yield
- 0.00%
- Gross Margin
- 85.53%
- Op Margin
- 33.23%
- Net Margin
- 30.70%
- ROE
- 20.08%
- ROIC
- 12.51%
Latest fiscal year · YoY change
- Revenue
- $12.00B+8.9%
- Gross Profit
- $10.35B+9.1%
- Op Income
- $4.17B
- Net Income
- $3.95B+838.1%
- EPS
- $15.46+843.3%
- OCF Growth
- +837.2%
- FCF Growth
- +504.1%
- 52W High
- $568.67
- 52W Low
- $412.27
- 50D MA
- $522.74
- 200D MA
- $484.60
- Beta
- 0.32
- RSI (14)
- 41
- Avg Volume
- 1.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vertex posted another strong quarter with 12% revenue growth, continued CF strength, and growing contributions from CASGEVY, JOURNAVX, and newly added Palsonify, while setting up a potential fifth pillar with povitacept in renal.· November 2, 2026
- Q3 revenue grew 12% year over year, with growth from the U.S. and international markets, CF, newer launches, and a September contribution from Palsonify.
- Non-GAAP EPS was $4.76, with non-GAAP gross margin of 85.6%; GAAP gross margin was 84.7%.
- ALYFTREK continued to ramp, with $706 million in worldwide sales in Q3 and more than $1 billion in U.S. year-to-date sales.
- CASGEVY generated $99 million in Q3 revenue, JOURNAVX generated more than $58 million, and Palsonify contributed about $24 million in Q3.
- Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion and lifted operating expense guidance to about $6 billion, mainly due to Crinetics integration.
- Management said povitacept is on track for a November 30 PDUFA date and described launch readiness as complete.
Vertex reported third-quarter total revenue growth of 12% year over year, including 10% growth in the U.S. and 16% internationally; CF revenue grew 8% globally, with 5% growth in the U.S. and 12% outside the U.S. (10% on a constant-currency basis). Non-GAAP gross margin was 85.6%, GAAP gross margin was 84.7%, non-GAAP net income was $1.21 billion, and non-GAAP EPS was $4.76. Non-GAAP R&D expense was $936 million, non-GAAP SG&A was $556 million, and the company recorded $41 million in acquired IPR&D expense. Vertex ended the quarter with approximately $9.8 billion in cash and investments. For full-year 2026, Vertex raised revenue guidance from $13.1 billion-$13.2 billion to $13.15 billion-$13.25 billion, including an expected $40 million-$50 million contribution from Crinetics. The company continued to expect gross margin slightly below 86%, non-GAAP operating expenses of approximately $6 billion, total non-operating costs of $105 million tied to Crinetics financing, interest income about $60 million lower than otherwise due to lower cash balances, and a full-year non-GAAP tax rate of 19.5%-20.5%.
Reshma Kewalramani emphasized that Vertex is evolving from a CF-focused company into a multi-disease commercial platform, saying revenue growth was balanced across geography and product lines and that rare endocrinology is now the fourth commercial pillar with renal potentially becoming the fifth. She highlighted ongoing pipeline progress in CF, pain, T1D, and renal, and repeatedly framed recent data as supportive of durable long-term growth. Her tone was upbeat and confident, especially around ALYFTREK, povitacept, and the company’s ability to keep expanding across multiple franchises.
Charles Wagner said Q3 revenue rose 12% year over year, with 1 point of favorable FX and $10 million from Crinetics included in the quarter. He cited non-GAAP gross margin of 85.6%, R&D of $936 million, SG&A of $556 million, $41 million of acquired IPR&D, and non-GAAP EPS of $4.76. On the balance sheet, he noted about $9.8 billion of cash and investments after closing Crinetics, $4.5 billion of term loans at roughly 4.8% interest, $120 million of share repurchases in the quarter, and $921 million of buybacks year to date. He also explained that guidance increases were mainly due to Crinetics integration, with revenue lifted modestly and operating expenses moved to about $6 billion.
Analysts focused heavily on povitacept label, manufacturing, and launch questions, especially a citizen petition about IgG monitoring and whether trial dose-hold rules need to carry into practice. Management said the FDA review is proceeding normally, they feel good about the filing and manufacturing, and emphasized that infections were balanced with no opportunistic infections in the program. Another major topic was anaxaplin/AMPLITUDE: management said a statistically significant GFR-slope result is the key bar for success because that is the FDA-agreed accelerated-approval endpoint. Questions also covered JOURNAVX gross-to-net and PSP timing, where management said the patient support program stays on until mid-2027, after which gross-to-net should normalize to around 50% to 60%.
The call showed multiple sources of growth already contributing to Vertex beyond CF: ALYFTREK is scaling, CASGEVY and JOURNAVX are growing, and Palsonify is off to an early launch. Management sounded confident that povitacept could become a differentiated renal product, citing strong efficacy, convenient at-home dosing, and positive physician and payer feedback ahead of the PDUFA date.
Several products still face execution and development risk: JOURNAVX revenue is being distorted by the patient support program and access rollout, and management does not expect gross-to-net normalization until mid-2027. Povitacept still depends on regulatory approval and manufacturing review, while anaxaplin’s value case hinges on future GFR-slope data and regulatory acceptance. In CF, Vertex is not yet ready to advance VX-828 alone and is waiting on the rest of the next-gen 3.0 data before deciding next steps.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 253.54M
- Float Shares
- 252.96M
of shares held by institutions
1,831 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VRTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| David TaylorHouse · OH02 | Sell | Aug 26, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| David TaylorHouse · OH02 | Sell | Jan 29, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| David TaylorHouse · OH02 | Buy | Aug 7, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 10, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capital World Investors | 25.97M | ▼ 148.22K |
| Vanguard Group Inc | 24.11M | ▼ 111.04K |
| Blackrock, Inc. | 23.80M | ▼ 306.26K |
| Capital Research Global Investors | 17.81M | ▼ 1.68M |
| Vanguard Capital Management LLC | 16.60M | ▲ 15.27K |
| State Street Corp | 12.02M | ▲ 153.00K |
| Invesco Ltd. | 8.28M | ▲ 237.95K |
| Geode Capital Management, LLC | 6.08M | ▲ 64.12K |
| Jpmorgan Chase & Co | 5.69M | ▼ 825.91K |
| Capital International Investors | 5.06M | ▲ 364.04K |
| Vanguard Portfolio Management LLC | 4.94M | ▲ 65.63K |
| Franklin Templeton Inc | 4.46M | ▲ 1.11M |
Held by 2,563 ETFs
Biggest fund positions in VRTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Thornberry Nancy | sell | 1,000 |
| Nov 16, 26 | Bhatia Sangeeta N. | sell | 271 |
| Nov 12, 26 | WAGNER CHARLES F JR | sell | 15,286 |
| Nov 6, 26 | Kewalramani Reshma | sell | 11,866 |
| Oct 20, 26 | Brennan Daniel J. | other | 795 |
| Oct 20, 26 | Brennan Daniel J. | other | 0 |
| Oct 15, 26 | SACHS BRUCE I | other | 92.694 |
| Oct 15, 26 | Garber Alan M | other | 29.272 |
| Sep 8, 26 | van Grunsven Jasper | other | 8,682 |
| Sep 8, 26 | van Grunsven Jasper | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRTX coverage
Recent articles, reports, and earnings notes.

Vertex Pharmaceuticals (VRTX): CF Cash Engine Funds New Growth
Vertex is using its dominant cystic fibrosis franchise to fund expansion into gene editing, pain, and endocrinology. The stock looks fairly valued near consensus, making execution on ALYFTREK and new launches the key debate.

Vertex Pharmaceuticals Incorporated (VRTX) slips: deep earnings analys
Vertex Pharmaceuticals Incorporated (VRTX) slips after a mixed quarter, but the deeper read shows revenue beat, a modest EPS miss, and strong cystic fibrosis momentum. This analysis breaks down ALYFTREK growth, pipeline traction, updated guidance, and what the earnings details may mean for the stock.

Vertex Pharmaceuticals Incorporated (VRTX) gains on earnings misses
Vertex Pharmaceuticals Incorporated (VRTX) gains 0.5% after earnings misses, as investors weigh the latest results against the stock’s modest move higher.
Want a deeper read on VRTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 17
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
5,362 Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banco Santander S.A.
defenseworld.net · Nov 17
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 13
Impax Small Cap Fund Q3 2026 Portfolio Review
seekingalpha.com · Nov 12
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
zacks.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice